HARNESSING THE POWER OF MACROPHAGES
May 2024
Cautionary Note Regarding Forward-Looking Statements
Statements in this slide deck about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to,
statements relating to Carisma's business, strategy, future operations, cash runway, the advancement of Carisma's product candidates and product pipeline, and clinical development of Carisma's product candidates, including expectations regarding timing of initiation and results of clinical trials. The words ""anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goals," "intend," "may," "might," "outlook," "plan," "project," "potential," "predict," "target," "possible," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, (i) Carisma's ability to obtain, maintain and protect its intellectual property rights related to its product candidates; (ii) Carisma's ability to advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials and with its current financial and human resources; (iii) Carisma's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates;
- Carisma's ability to realize the anticipated benefits of its research and development programs, strategic partnerships, research and licensing programs and academic and other collaborations; (v) regulatory requirements or developments and Carisma's ability to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; (vi) changes to clinical trial designs and regulatory pathways; (vii) risks associated with Carisma's ability to manage expenses; (viii) changes in capital resource requirements; (ix) risks related to the inability of Carisma to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; and (x) legislative, regulatory, political and economic developments. . For a discussion of these risks and uncertainties, and other important factors, any of which could cause Carisma's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Carisma's other recent filings with the Securities and Exchange Commission. Any forward-looking statements that are made in this presentation speak as of the date of this presentation. Carisma undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
2
Pioneering engineered macrophages in
oncology and beyond
Harnessing the Power of Macrophages
Developing unique and transformative cell therapies for patients with devastating diseases
+
+
+
• Focused development of CT-0525(CAR-Monocyte), which we believe is best suited to deliver benefit to | |||
HER2 | patients with HER2 over-expressing solid tumors refractory to available treatments | ||
Program | • | CT-0508 trial to conclude post Regimen 2 of sub-study in combination with pembrolizumab | |
• | CT-0525 data is expected end of 2024 | ||
Beyond | • In Vivo Oncology: Advancing multiple targets in our in vivo CAR-M program in collaboration with Moderna | ||
• | Fibrosis: Advancing an engineered macrophage in liver fibrosis, with preclinical proof of concept data | ||
HER2* | |||
expected in 2Q 2024 | |||
• Cash runway into 3Q 2025, funding multiple clinical and preclinical catalysts | |||
Corporate | • | Strong IP position | |
• Potential for collaborations (except in vivo oncology) | |||
- In late March 2024, Carisma made the decision to pause further development of CT-1119, pending additional financing MoA: Mechanism of Action
4
CAR-M: Differentiated from CAR-T and CAR-NK
CAR-M has the potential for key solid tumor advantages over both
CAR-T | CAR-NK | CAR-M | |
Mechanism of Action | |||
Effector Cell | CD4/CD8 T cells | Natural Killer Cells | Macrophages or Monocytes |
Persistence | High | Low | Intermediate |
Trafficking Potential | Low | Low | High |
TME Activation | Low | Low | High |
Antigen Presentation | None | None | High |
Epitope Spreading | Low | Low | High |
Safety | |||
Chemotherapy Conditioning | Yes | Yes | No |
CRS / ICANS | High / High | Low / Low | Low / Low |
Manufacturing | |||
Manufacturing Time | Days to weeks | Days to weeks | Monocyte: 1 day |
5
First-in-Class Pipeline
Multiple value inflection points across therapeutic areas and modalities
THERAPEUTIC | PRODUCT | PLATFORM | DISCOVERY PRE-CLINICAL | PHASE 1 | PHASE 2 | PHASE 3 | COLLABORATOR | ||
AREA | CANDIDATE | ||||||||
Ex Vivo Oncology | |||||||||
CT-0525 | CAR-Monocyte | 4Q 2024: Initial data1 | |||||||
HER2+ | (1st Gen CAR) | ||||||||
solid tumors | CT-0508* | CAR-Macrophage | 2Q 2024: Combination data1 | ||||||
(1st Gen CAR) | ` | ||||||||
Mesothelin+ | CT-1119** | CAR-Monocyte | |||||||
solid tumors | (Next-Gen CAR2) | ||||||||
In Vivo Oncology
Solid Tumor Antigen3 | CAR-Macrophage + |
mRNA/LNP | |
Oncology | |
CAR-Macrophage + | |
4 Additional Targets4 | |
mRNA/LNP | |
Fibrosis and Immunology
Liver Fibrosis | TBD | Engineered | 2Q 2024: Preclinical proof of concept data1 |
macrophage | |||
- In late March 2024, Carisma made the decision to cease further development of CT-0508, including monotherapy and in combination with pembrolizumab
- In late March 2024, Carisma made the decision to pause further development of CT-1119, pending additional financing
1. Anticipated milestones; 2. Includes SIRPα knockdown technology; 3. Target undisclosed
4. Moderna collaboration has identified 5 total oncology targets, with the option to identify an additional 7 oncology targets; First lead candidate was nominated in 4Q 2023
6
Drive to 2025
Leverage world-leading macrophage engineering platform to deliver three product opportunities
Program
2024 Tactical Plan
2025 Objectives
HER2 CAR-M
CT-05251 | Safety Study Cohort 1: | 3 Billion Cells | Phase II/III Regimen Identified2 |
CT-05251 | Safety Study Cohort 2: | 10 Billion Cells | |
In vivo CAR-M | IND-enabling activities for lead candidate |
(Collaboration with Moderna) | Pre-clinical studies for additional identified targets |
Undisclosed Development &
Regulatory Milestones
Liver Fibrosis
Pre-clinicalproof-of-concept studies Development candidate identified
IND-enabling Activities
1. CAR-Monocyte; 2. In late March 2024, the Company selected CAR-Monocyte approach for the Phase II/III Regimen Identified
7
Targeting HER2:
CT-0525 and CT-0508
HER2 Development Strategy
CT-0525 selected as HER2 product candidate, with additional considerations to be informed by ongoing studies
Demonstrate Safety, Tolerability,
Feasibility & MOA:
CAR-Macrophage(CT-0508*)
Phase 1: No Further Data Expected
Overcome T Cell Exhaustion:
CAR-Macrophage(CT-0508) +
Pembrolizumab
Phase 1: Data Expected 2Q'24
Increase Dose:
CAR-Monocyte(CT-0525)
Phase 1: Initial Data Expected 4Q'24
Potential Registrational Profile
Cell | Monotherapy | Line of | Tumor | |||
Dose | vs. Combo | |||||
Type | Therapy | Type | ||||
Therapy | ||||||
MOA: Mechanism of Action
* In late March 2024, Carisma made the decision to cease further development of CT-0508, including monotherapy and in combination with pembrolizumab
9
CT-0525
CT-0525: HER2 Targeted CAR-Monocyte(Macrophage Precursor)
Potential to significantly improve upon the observed biological activity of CT-0508
Highlights
Key Manufacturing Advantages Over CAR-Macrophage
- Higher cell numbers
- Faster manufacturing (1 day)
- Reduced COGS
Potential Biological Advantages Over CAR-Macrophage
- 2,000-foldincreased exposure
- Cell count, trafficking, and persistence
- Increased potency
- Killing, cytokine release, and antigen presentation
- Dosing flexibility
Development Plan & Timeline
✓ IND cleared
• First patient expected to be treated in 2Q 2024
- Initial data expected in 4Q 2024
CT-0525 | CAR COMPONENTS | |
Humanized anti-HER2 scFv
CD8 Hinge
CD8 TM
CD3-zeta
TECHNICALS: CT-0508 | CT-0525 Product Description | |
Cells | Autologous monocytes |
Vector | Ad5f35 |
Phenotype | M1 |
CAR | 1st Generation |
* Compared to CAR-Macrophage
10
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Carisma Therapeutics Inc. published this content on 01 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 May 2024 12:58:29 UTC.